<a href="https://www.fiercebiotech.com/biotech/struggling-liminatus-pays-320m-stock-car-t-biotech-innocs-ai" hreflang="en">Struggling Liminatus pays $320M in stock for CAR-T biotech InnocsAI</a>
fiercebiotech.com·May 21, 2026
Liminatus Pharma has announced a $320 million share acquisition of CAR-T biotech company InnocsAI to enhance its cancer immunotherapy portfolio.
This acquisition highlights a growing trend of integration between traditional biotech companies and AI-driven approaches in drug discovery, specifically in the CAR-T space. It suggests a strategic move towards leveraging AI to enhance cancer immunotherapy development, emphasizing the potential for AI to accelerate innovation and improve outcomes in precision medicine.